Publications by authors named "M Brytting"
Influenza causes seasonal epidemics of respiratory infection in all parts of the world. Manifestations of influenza range from mild upper to severe lower respiratory tract infection. Medical risk groups are defined by factors predisposing for development of severe disease and are recommended annual vaccination as a protective measure.
View Article and Find Full Text PDFBackgroundTimely treatment with neuraminidase inhibitors (NAI) can reduce severe outcomes in influenza patients.AimWe assessed the impact of antiviral treatment on in-hospital deaths of laboratory-confirmed influenza patients in 11 European Union countries from 2010/11 to 2019/20.MethodsCase-based surveillance data from hospitalised patients with known age, sex, outcome, ward, vaccination status, timing of antiviral treatment, and hospitalisation were obtained.
View Article and Find Full Text PDFArticle Synopsis
- - The study examined how primary care influenza surveillance networks in Europe adapted to include COVID-19 monitoring during the early phases of the pandemic, focusing on seven sentinel sites across five countries.
- - Different levels of adaptations were reported: substantial changes in two sites, moderate in two, and minor in three, mainly involving adjustments to patient referrals, sample collection, and data collection processes.
- - Key takeaways included the importance of flexibility in establishing new routines, the need for collaborative networks, and a balance between rapid pandemic response needs and regular surveillance goals.
IntroductionIn July and August 2021, the SARS-CoV-2 Delta variant dominated in Europe.AimUsing a multicentre test-negative study, we measured COVID-19 vaccine effectiveness (VE) against symptomatic infection.MethodsIndividuals with COVID-19 or acute respiratory symptoms at primary care/community level in 10 European countries were tested for SARS-CoV-2.
View Article and Find Full Text PDF